Expert review of vaccines
-
Expert review of vaccines · Jun 2012
Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
Cervical cancer is the third most common cancer in women worldwide and often affects women under 40 years of age with young families. Vaccination against HPV is a major advancement, as it offers primary prevention against the infectious agent that is the main cause of the disease. ⋯ The vaccine's antibody response profile suggests a long duration of immunity. Safety data have been reassuring, which is not unexpected, given that the vaccine is composed of virus-like particles, rather than being a live-virus vaccine.